Data / Form D filings / IntelGenx Technologies Corp.
IntelGenx Technologies Corp.: Form D filings
IntelGenx Technologies Corp., a pharmaceuticals company in Ville Saint Laurent, Quebec, Canada, filed 7 Form D notices with the SEC between 2011 and 2023. The latest, on March 28, 2023, reports $763,000 sold of a $2 million offering to 26 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 6420 ABRAMS, Ville Saint Laurent, Quebec, Canada, H4S 1
- Phone
- (514) 331-7440
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1098880
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 28, 2023 | New notice | $2,000,000 | $763,000 | $1,237,000 | 26 | Mar 21, 2023 | sec.gov |
| Sep 10, 2021 | Amendment | $2,500,000 | $2,101,000 | $399,000 | 34 | Aug 5, 2021 | sec.gov |
| Aug 17, 2021 | New notice | $2,101,000 | $2,101,000 | 34 | Aug 5, 2021 | sec.gov | |
| Oct 27, 2020 | New notice | $2,000,000 | $1,762,000 | $238,000 | 53 | Oct 15, 2020 | sec.gov |
| May 17, 2018 | New notice | $4,005,696 | $2,480,000 | $1,525,696 | 38 | May 8, 2018 | sec.gov |
| Jun 29, 2011 | Amendment | $1,730,298 | $1,730,298 | 20 | Jun 21, 2011 | sec.gov | |
| Jun 28, 2011 | New notice | $1,730,298 | $1,730,298 | 20 | Jun 21, 2011 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Horst G. Zerbe | Executive Officer, Director | |
| Srinivas J. Rao | Director | |
| Clemens J. Mayr | Director | |
| Andre G. Godin | Executive Officer | |
| J. Bernard G. Boudreau | Director | |
| Bernd J. Melchers | Director | |
| Frank J. Stegert | Director | |
| Monika J. Trzcinska | Director | |
| Mark J. Nawacki | Director |
Every Form D from the week of Mar 27, 2023 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what IntelGenx Technologies Corp. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.